{'fraction_non_alphanumeric': 0.04901293396868618, 'fraction_numerical': 0.041524846834581346, 'mean_word_length': 5.25531914893617, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolic syndrome correlates with significantly adverse disease outcomes in COVID-19 patients during the second wave of pandemic

Background: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The goal of this study was to investigate the risk and mortality of COVID-19 patients with Metabolic Syndrome especially during the second wave of pandemic. Methods: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The record of COVID-19 patients admitted during the second wave of pandemic (April – June, 2021) were included and analyzed for Metabolic syndrome, Demographic characteristics and Clinical Outcomes. Comorbidities were classified into the following Groups: DM (having DM with or without comorbidities), only DM (having DM without other comorbidities); HT (having HT with or without other comorbidities), only HT (having HT without other comorbidities); CVD (having CVD with or without comorbidities), only CVD (having CVD without other comorbidities). Correlation analysis was also done for sub-groups of DM+CVD, CVD+HT, HT+DM, (with or without other comorbidities). Results: Among 994 Patients with COVID-19, 748/994 (75.25%) were discharged as cured and 246 (24.74%) succumbed to death. The mean age of the study population was 52.64±14.72, in which 366 (36.82%) were Females and 628/994 (63.57%) were Males. 